Literature DB >> 18511178

Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.

Kurt G Naber1, Giancarlo Schito, Henry Botto, Juan Palou, Teresita Mazzei.   

Abstract

BACKGROUND: Uncomplicated cystitis in females is among the most frequent infections in community.
OBJECTIVE: To determine clinical aspects, epidemiology, and antimicrobial susceptibility of uropathogens. INTERVENTION: Patients were investigated clinically and with urinalysis and urine culture. MEASUREMENTS: This survey started in 2003 and ended in 2006 including 68 centres in nine European countries and in Brazil. Female patients between 18 and 65 yr with symptoms of uncomplicated cystitis were consecutively enrolled and clinically evaluated. Uropathogens were identified and their susceptibility tested for nine antimicrobials. RESULTS AND LIMITATIONS: Clinical data of 4264 eligible patients were analysed. A positive urine culture was found in 74.6%. Within the 3018 pathogens, Escherichia coli (E. coli) was most frequent (76.7%), followed by Enterococcus faecalis (4.0%), Staphylococcus saprophyticus (3.6%), Klebsiella pneumoniae (3.5%), and Proteus mirabilis (3.5%). E. coli showed the highest rate of susceptibility to fosfomycin (98.1%) followed by mecillinam (95.8%), nitrofurantoin (95.2%), and ciprofloxacin (91.8%). The lowest rate was found for ampicillin (45.1%). For the total spectrum the order was fosfomycin (96.4%), mecillinam (95.9%), ciprofloxacin (90.3%), and nitrofurantoin (87.0%). In all countries a susceptibility rate to E. coli above 90% was found only for fosfomycin, mecillinam, and nitrofurantoin. The susceptibility rates varied significantly from country to country (p<0.0001), except for fosfomycin, mecillinam, and nitrofurantoin.
CONCLUSIONS: Despite wide cross-country variability of bacterial susceptibility/resistance rates to the other antimicrobials tested, fosfomycin, mecillinam, and nitrofurantoin have preserved their in vitro activity in all countries investigated. They may represent good options for the empiric therapy of female patients with uncomplicated cystitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511178     DOI: 10.1016/j.eururo.2008.05.010

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  71 in total

1.  Uropathogen distribution and antimicrobial susceptibility in uncomplicated cystitis in Belgium, a high antibiotics prescribing country: 20-year surveillance.

Authors:  S Heytens; J Boelens; G Claeys; A DeSutter; T Christiaens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-17       Impact factor: 3.267

Review 2.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

3.  Prescribing behavior in urinary tract infection: inadequate implementation of guidelines in clinical practice.

Authors:  Florian M E Wagenlehner; Kurt G Naber
Journal:  Dtsch Arztebl Int       Date:  2012-12-14       Impact factor: 5.594

4.  Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.

Authors:  G Bonkat; G Müller; O Braissant; R Frei; S Tschudin-Suter; M Rieken; S Wyler; T C Gasser; A Bachmann; A F Widmer
Journal:  World J Urol       Date:  2013-01-29       Impact factor: 4.226

Review 5.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

6.  Antimicrobial resistance in community-acquired Escherichia coli isolated from urinary infection: Good news or bad?

Authors:  Lindsay E Nicolle
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

7.  [New aspects on diagnostics and therapy of uncomplicated cystitis].

Authors:  K G Naber
Journal:  Urologe A       Date:  2014-10       Impact factor: 0.639

8.  Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers.

Authors:  Florian M E Wagenlehner; Fabian Münch; Adrian Pilatz; Birte Bärmann; Wolfgang Weidner; Christine M Wagenlehner; Marion Straubinger; Holger Blenk; Wolfgang Pfister; Michael Kresken; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

9.  Prevalence and risk factors for extended spectrum Beta-lactamase-producing uropathogens in patients with urinary tract infection.

Authors:  Dong Sup Lee; Chung Bum Lee; Seung-Ju Lee
Journal:  Korean J Urol       Date:  2010-07-20

10.  [Clinical aspects and epidemiology of uncomplicated cystitis in women. German results of the ARESC Study].

Authors:  F M E Wagenlehner; C Wagenlehner; O Savov; L Gualco; G Schito; K G Naber
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.